Routine

Gender-affirming hormone therapy

GAHT · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Hormonal treatment to align secondary sexual characteristics with gender identity in transgender and gender-diverse adults, using oestrogen (with antiandrogen) or testosterone. Requires informed consent, baseline risk assessment and ongoing monitoring.

Red flags

  • Symptoms/signs of venous thromboembolism (oestrogen)
  • Haematocrit above threshold (testosterone-induced polycythaemia)
  • New severe headache/visual change (prolactinoma on oestrogen)
  • Marked transaminase rise
  • Uncontrolled cardiovascular disease

Assessment

Differential diagnosis

  • Other causes of gender dysphoria mimics
  • Endocrine conditions needing exclusion before therapy (e.g. prolactinoma)
  • Secondary causes of hypogonadism

Investigations

  • Baseline hormone profile (testosterone, oestradiol, LH/FSH)
  • Metabolic screen: lipids, glucose/HbA1c, liver and renal function
  • Full blood count (haematocrit for testosterone)
  • Prolactin (before/during oestrogen)
  • VTE and cardiovascular risk assessment; bone density if long-term hypogonadism

Management

  • Confirm informed consent and assess cardiovascular, thrombotic and cancer risk
  • Address modifiable risks (smoking cessation particularly before oestrogen)
  • For feminising therapy, start oestradiol and add an antiandrogen to suppress testosterone
  • For masculinising therapy, start testosterone and titrate to male physiological range
  • Set realistic timelines for reversible and irreversible changes and discuss fertility preservation
  • Monitor hormone levels and titrate to target ranges
  • Screen for polycythaemia (testosterone) and VTE/prolactin (oestrogen)
  • Continue age/anatomy-appropriate cancer screening
  • Review bone health with prolonged therapy
  • Coordinate with any planned surgical care and adjust therapy accordingly

Drugs & doses

Estradiol valerate 2-6 mg PO daily or transdermal estradiol patch/gel titrated
Antiandrogen: spironolactone 100-200 mg PO daily or cyproterone acetate low dose (or GnRH analogue)
Testosterone gel daily or testosterone undecanoate IM 1000 mg every 10-14 weeks
GnRH analogue (e.g. leuprorelin/goserelin) for gonadal suppression where used

Disposition

Provide through gender/endocrine services with informed consent and shared monitoring; refer for fertility counselling and surgical pathways as desired.

Complications & pitfalls

  • Venous thromboembolism (oestrogen, worse with smoking/oral route)
  • Polycythaemia (testosterone)
  • Hyperprolactinaemia
  • Dyslipidaemia/cardiovascular risk changes
  • Reduced fertility/bone loss if gonadal suppression without adequate replacement

Exam pearls

  • Transdermal oestrogen lowers VTE risk compared with oral, especially in smokers and older patients
  • Discuss and offer fertility preservation before starting therapy, as some effects are irreversible
  • Monitor haematocrit on testosterone and prolactin on oestrogen
  • Maintain anatomy-appropriate cancer screening regardless of gender identity

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.